Emavusertib
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Emavusertib, covering 2026-03-30 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) [Phase 1, Phase 2]